Movement Alert｜Merck Rises 3.08% in Regular Trading, Keytruda Plus Trodelvy Wins FDA Approval for Triple-Negative Breast Cancer

Market Focus02:11

On June 25, Merck rose 3.08% in regular trading, trading at $124.375/share, with turnover of $683 million. Multiple positive catalysts converged to drive the stock higher.

On the news front, the FDA approved Keytruda and Keytruda Qlex in combination with Trodelvy for the first-line treatment of PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer. This marks the first approved PD-1 inhibitor plus Trop-2-directed antibody-drug conjugate regimen in this indication. Phase 3 data showed the combination reduced the risk of disease progression or death by 35% versus Keytruda plus chemotherapy, with median progression-free survival improving to 11.2 months from 7.8 months.

Additionally, the European Commission approved Keytruda plus Padcev for muscle-invasive bladder cancer patients ineligible for cisplatin, showing a 60% lower risk of event-free survival events and 50% lower risk of death versus surgery alone. Merck also received approval in China for a platinum-resistant ovarian cancer indication, while CICC initiated coverage with an Outperform rating and a $138 target price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102387344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102387344","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Merck Rises 3.08% in Regular Trading, Keytruda Plus Trodelvy Wins FDA Approval for Triple-Negative Breast Cancer","media":"Market Focus","content":"<p><p>On June 25, Merck rose 3.08% in regular trading, trading at $124.375/share, with turnover of $683 million. Multiple positive catalysts converged to drive the stock higher.</p><p>On the news front, the FDA approved Keytruda and Keytruda Qlex in combination with Trodelvy for the first-line treatment of PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer. This marks the first approved PD-1 inhibitor plus Trop-2-directed antibody-drug conjugate regimen in this indication. Phase 3 data showed the combination reduced the risk of disease progression or death by 35% versus Keytruda plus chemotherapy, with median progression-free survival improving to 11.2 months from 7.8 months.</p><p>Additionally, the European Commission approved Keytruda plus Padcev for muscle-invasive bladder cancer patients ineligible for cisplatin, showing a 60% lower risk of event-free survival events and 50% lower risk of death versus surgery alone. Merck also received approval in China for a platinum-resistant ovarian cancer indication, while CICC initiated coverage with an Outperform rating and a $138 target price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Merck Rises 3.08% in Regular Trading, Keytruda Plus Trodelvy Wins FDA Approval for Triple-Negative Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Merck Rises 3.08% in Regular Trading, Keytruda Plus Trodelvy Wins FDA Approval for Triple-Negative Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 02:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Merck rose 3.08% in regular trading, trading at $124.375/share, with turnover of $683 million. Multiple positive catalysts converged to drive the stock higher.</p><p>On the news front, the FDA approved Keytruda and Keytruda Qlex in combination with Trodelvy for the first-line treatment of PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer. This marks the first approved PD-1 inhibitor plus Trop-2-directed antibody-drug conjugate regimen in this indication. Phase 3 data showed the combination reduced the risk of disease progression or death by 35% versus Keytruda plus chemotherapy, with median progression-free survival improving to 11.2 months from 7.8 months.</p><p>Additionally, the European Commission approved Keytruda plus Padcev for muscle-invasive bladder cancer patients ineligible for cisplatin, showing a 60% lower risk of event-free survival events and 50% lower risk of death versus surgery alone. Merck also received approval in China for a platinum-resistant ovarian cancer indication, while CICC initiated coverage with an Outperform rating and a $138 target price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1102387344","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102387344","pubTimestamp":1782411113,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Merck rose 3.08% in regular trading, trading at $124.375/share, with turnover of $683 million. Multiple positive catalysts converged to drive the stock higher.On the news front, the FDA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"动向提示|默沙东常规交易涨3.08%Keytruda加Trodelvy获FDA批准用于三阴性乳腺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"On June 25, Merck rose 3.08% in regular trading, trading at $124.375/share, with turnover of $683 million. Multiple positive catalysts converged to drive the stock higher.On the news front, the FDA approved Keytruda and Keytruda Qlex in combination with Trodelvy for the first-line treatment of PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer. This marks the first approved PD-1 inhibitor plus Trop-2-directed antibody-drug conjugate regimen in this indication. Phase 3 data showed the combination reduced the risk of disease progression or death by 35% versus Keytruda plus chemotherapy, with median progression-free survival improving to 11.2 months from 7.8 months.Additionally, the European Commission approved Keytruda plus Padcev for muscle-invasive bladder cancer patients ineligible for cisplatin, showing a 60% lower risk of event-free survival events and 50% lower risk of death versus surgery alone. Merck also received approval in China for a platinum-resistant ovarian cancer indication, while CICC initiated coverage with an Outperform rating and a $138 target price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102387344","isCrawlerRequest":true}